The Filing Desk

AbCellera Biologics vs Vivani Medical

AbCellera Biologics ABCL · Vivani Medical VANI · Biotechnology

Free cash flow was −$174 million at AbCellera Biologics and −$25 million at Vivani Medical.

Side by side

AbCellera BiologicsVivani Medical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$75M$0M
Revenue growth160.6%—
Revenue growth a year, last 5 years−20.3%—
Gross margin——
Operating margin−289.0%—
Net margin−194.9%—
Free cash flow−$174M−$25M
Free cash flow margin−231.7%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.5%13.5%
Last close$10.47$1.09
P/E at the last close——
Insider trades, last 12 monthsbought $2.7 million, sold $0bought $16.7 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbCellera BiologicsVivani Medical
Operating margin
Percent of revenue
AbCellera BiologicsVivani Medical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbCellera BiologicsVivani Medical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbCellera Biologics and Vivani Medical pages.